Department of Clinical Medicine, University of Bergen, 5009 Bergen, Norway.
Neuro-SysMed, Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.
Int J Mol Sci. 2024 Jan 23;25(3):1365. doi: 10.3390/ijms25031365.
In multiple sclerosis (MS), there is a great need for treatment with the ability to suppress compartmentalized inflammation within the central nervous system (CNS) and to promote remyelination and regeneration. Mesenchymal stem cells (MSCs) represent a promising therapeutic option, as they have been shown to migrate to the site of CNS injury and exert neuroprotective properties, including immunomodulation, neurotrophic factor secretion, and endogenous neural stem cell stimulation. This review summarizes the current understanding of the underlying neuroprotective mechanisms and discusses the translation of MSC transplantation and their derivatives from pre-clinical demyelinating models to clinical trials with MS patients.
在多发性硬化症(MS)中,非常需要能够抑制中枢神经系统(CNS)内局部炎症并促进髓鞘再生和再生的治疗方法。间充质干细胞(MSCs)代表了一种有前途的治疗选择,因为它们已被证明可以迁移到 CNS 损伤部位,并发挥神经保护特性,包括免疫调节、神经营养因子分泌和内源性神经干细胞刺激。这篇综述总结了目前对潜在神经保护机制的理解,并讨论了 MSC 移植及其衍生物从脱髓鞘模型的临床前研究向 MS 患者临床试验的转化。